Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 14/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10108812 | 0.82 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3HTR2CTACR1 | |
| SCHEMBL10109021 | 0.81 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13676866 | 0.80 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL10108852 | 0.79 | SLC6A2 (0.61) | SLC6A2SLC6A4SLC6A3HTR2C | |
| SCHEMBL13676838 | 0.78 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL312581 | 0.77 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3HTR2CTACR1 | |
| SCHEMBL312594 | 0.76 | SLC6A2 (0.74) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10108840 | 0.75 | SLC6A4 (0.46) | SLC6A2SLC6A4SLC6A3HTR2CTACR1 | |
| SCHEMBL13676842 | 0.74 | SLC6A4 (0.45) | SLC6A2SLC6A4SLC6A3TACR1 | |
| SCHEMBL10108882 | 0.73 | SLC6A4 (0.46) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093285-B2 | Aminopiperidinyl derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090247568-A1 | AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247568-A1 | AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF | MAOB, ADORA2B, HTR1B | SLC6A2 8/4885SLC6A4 33/4885SLC6A3 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.